Hyperpolarized Xenon MRI for Chronic Obstructive Pulmonary Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how a special type of MRI, using hyperpolarized xenon gas, can enhance understanding of lung function in people with Chronic Obstructive Pulmonary Disease (COPD) undergoing treatment with endobronchial valves. These tiny devices are placed in the lungs to improve breathing. The researchers aim to assess the valves' effectiveness by comparing lung images before and after treatment. The trial seeks COPD patients already scheduled for endobronchial valve therapy who are willing to participate in follow-up visits and tests. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to contribute to groundbreaking insights.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What prior data suggests that hyperpolarized xenon MRI is safe for assessing lung function in COPD patients?
Research has shown that hyperpolarized xenon-129 MRI for lung imaging is generally safe and well-tolerated. Studies involving both healthy individuals and those with Chronic Obstructive Pulmonary Disease (COPD) reported no serious side effects. This imaging method allows doctors to assess lung function by using xenon-129, a special gas that is safe to inhale.
Although researchers continue to study hyperpolarized xenon-129 MRI, current evidence suggests it is safe for participants. This conclusion is based on past research where participants did not experience significant side effects from the imaging process. Prospective participants can feel confident about its safety.12345Why are researchers excited about this trial?
Researchers are excited about the MagniXene Hyperpolarized Xenon MRI because it offers a new way to assess lung function in COPD patients, especially those treated with endobronchial valves. Unlike other imaging techniques, this method uses hyperpolarized xenon gas, which provides clearer and more detailed images of the lungs. This allows doctors to see how well the lungs are functioning both before and after treatment, potentially leading to more personalized and effective care for patients with COPD.
What evidence suggests that hyperpolarized xenon MRI is effective for assessing lung function in COPD patients?
Research shows that hyperpolarized xenon-129 MRI, such as MagniXene, can evaluate lung function in people with chronic obstructive pulmonary disease (COPD). This imaging method reveals how well different parts of the lungs work by showing air replacement during breathing and oxygen levels in the lungs. This understanding clarifies how COPD affects lung tissue and airflow. In this trial, participants will undergo hyperpolarized xenon MRI assessments to monitor changes in lung function after treatments like endobronchial valve therapy, which may improve breathing in COPD patients.23567
Who Is on the Research Team?
Kevin Ma, MD
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for COPD patients who are scheduled to receive endobronchial valve therapy. Participants must be alert, cooperative, and willing to return for all scheduled visits and tests.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Imaging
Participants undergo baseline imaging with hyperpolarized xenon-129 MRI prior to receiving endobronchial valve therapy
Post-EBV Imaging
Participants undergo follow-up imaging with hyperpolarized xenon-129 MRI approximately 45 days after receiving endobronchial valve therapy
Follow-up
Participants are monitored for lung function changes and safety after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MagniXene Hyperpolarized Xenon MRI
Find a Clinic Near You
Who Is Running the Clinical Trial?
Xemed LLC
Lead Sponsor
University of Pennsylvania
Collaborator